Aavatar Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aavatar Therapeutics Inc. - overview
Established
2020
Location
Hanam, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2020 and based in Gyeonggi-do, South Korea, Aavatar Therapeutics Inc. operates as a biotechnology company that develops nanoparticle-based products as agents to treat genetic diseases. As of November 2023, the company is being led by its CEO, Seunghee Cho. In September 2026, Aavatar Therapeutics Inc.
raised KRW 5 billion in series B funding from HB Investment. The round was part of a larger KRW 25 billion series B funding. The firm develops and offers a gene therapy platform based on artificial intelligence (AI) and deep learning that provides individual diagnoses based on their disease and offers gene therapy products created using nanoparticles to offer therapies. The company creates drugs using capsid engineering and promoter engineering technologies.
he company will use the funding to further develop its AAV-based gene therapy platform. HB Investment backed the company based on its next-generation capsid engineering technology and experienced gene therapy development team.
Current Investors
Smilegate Investment, Shinhan Capital, WONIK Investment Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
https://www.aavatartps.com/
Verticals
Artificial Intelligence
Company Stage
Series B
Total Amount Raised
Subscriber access only
Aavatar Therapeutics Inc. - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Aavatar Therapeutics Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B | Completed | Aavatar Therapeutics Inc. | - | ||||||||
| Series A | Completed | Aavatar Therapeutics Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.